Top

Published in:

Open Access 01-12-2021 | Sulfonylurea | Research

Older people’s attitudes towards deprescribing cardiometabolic medication

Authors: Stijn Crutzen, Jamila Abou, Sanne E. Smits, Gert Baas, Jacqueline G. Hugtenburg, Mette Heringa, Petra Denig, Katja Taxis

Published in: BMC Geriatrics | Issue 1/2021

Abstract

Background

Overtreatment with cardiometabolic medication in older patients can lead to major adverse events. Timely deprescribing of these medications is therefore essential. Self-reported willingness to stop medication is usually high among older people, still overtreatment with cardiometabolic medication is common and deprescribing is rarely initiated. An important barrier for deprescribing reported by general practitioners is the patients’ unwillingness to stop the medication. More insights are needed into the influence of patients’ characteristics on their attitudes towards deprescribing and differences in these attitudes between cardiometabolic medication groups.

Methods

A survey in older people using cardiometabolic medication using the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was performed. Participants completed the general rPATD and an adapted version for four medication groups. Linear and ordinal logistic regression were used to assess the influence of age, sex, therapeutic area and number of medications used on the patients’ general attitudes towards deprescribing. Univariate analysis was used to compare differences in deprescribing attitudes towards sulfonylureas, insulins, antihypertensive medication and statins.

Results

Overall, 314 out of 1143 invited participants completed the survey (median age 76 years, 54% female). Most participants (80%) were satisfied with their medication and willing to stop medications if their doctor said it was possible (88%). Age, sex and therapeutic area had no influence on the general attitudes towards deprescribing. Taking more than ten medicines was significantly associated with a higher perceived medication burden. Antihypertensive medication and insulin were considered more appropriate than statins, and insulin was considered more appropriate than sulfonylureas not favouring deprescribing.

Conclusions

The majority of older people using cardiometabolic medication are willing to stop one of their medicines if their doctor said it was possible. Health care providers should take into account that patients perceive some of their medication as more appropriate than other medication when discussing deprescribing.

Available only for authorised users

Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Cushman WC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. https://doi.org/10.1056/NEJMoa0802743.CrossRefPubMed

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):683–9.

Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med. 2014;174(8):1227–34. https://doi.org/10.1001/jamainternmed.2014.2894.CrossRefPubMedPubMedCentral

Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85. https://doi.org/10.1056/NEJMoa1001286.CrossRefPubMed

Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: Reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7(18):e009326.CrossRef

Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553–61.CrossRef

Kirkman SM, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60(12):2342–56. https://doi.org/10.1111/jgs.12035.CrossRefPubMedPubMedCentral

Mahoney GK, Henk HJ, McCoy RG. Severe hypoglycemia attributable to intensive glucose-lowering therapy among US adults with diabetes: population-based modeling study, 2011-2014. Mayo Clin Proc. 2019;94(9):1731–42. https://doi.org/10.1016/j.mayocp.2019.02.028.CrossRefPubMedPubMedCentral

10.

Banu Z, Lim KK, Kwan YH, Yap KZ, Ang HT, Tan CS, et al. Anti-hypertensive medications and injurious falls in an older population of low socioeconomic status: a nested case-control study. BMC Geriatr. 2018;18(1):1–9.CrossRef

11.

Sim JJ, Zhou H, Bhandari S, Wei R, Brettler JW, Tran-Nguyen J, et al. Low systolic blood pressure from treatment and association with serious falls/syncope. Am J Prev Med. 2018;55(4):488–96. https://doi.org/10.1016/j.amepre.2018.05.026.CrossRefPubMed

12.

Supiano MA, Williamson JD. New guidelines and SPRINT results: implications for geriatric hypertension. Circulation. 2019;140(12):976–8. https://doi.org/10.1161/CIRCULATIONAHA.119.037872.CrossRefPubMedPubMedCentral

13.

Scott IA, Hilmer SN, Le Couteur DG. Going beyond the guidelines in Individualising the use of antihypertensive drugs in older patients. Drugs Aging. 2019;36(8):675–85. https://doi.org/10.1007/s40266-019-00683-8.CrossRefPubMed

14.

Farrell B, Mangin D. Deprescribing is an essential part of good prescribing. Am Fam Physician. 2019;99(1):7–9.PubMed

15.

Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy. JAMA Intern Med. 2015;175(5):827–34. https://doi.org/10.1001/jamainternmed.2015.0324.CrossRefPubMed

16.

Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68. Available from:. https://doi.org/10.1111/bcp.12732.CrossRefPubMedPubMedCentral

17.

Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33(4):323–8. Available from:. https://doi.org/10.1002/jppr2003334323.CrossRef

18.

Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039–51. https://doi.org/10.1001/jama.2020.4871.CrossRefPubMedPubMedCentral

19.

Seidu S, Topsever P, Hambling CE, Cos FX, Khunti K. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes Metab. 2019;21:1668 Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13724.CrossRef

20.

Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes. J Diabetes Complicat. 2018;32(4):444–50. https://doi.org/10.1016/j.jdiacomp.2017.11.011.CrossRef

21.

Scott S, Clark A, Farrow C, May H, Patel M, Twigg MJ, et al. Attitudinal predictors of older peoples’ and caregivers’ desire to deprescribe in hospital. BMC Geriatr. 2019;19(1):1–11.CrossRef

22.

Reeve E, Low LF, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc. 2019;67(6):1204–10. https://doi.org/10.1111/jgs.15804.

23.

Reeve E, Thompson W, Farrell B. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11. https://doi.org/10.1016/j.ejim.2016.12.021.CrossRefPubMed

24.

Hart HE, Rutten GE, Bontje KN, Vos RC. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2018;20(4):1066–9. https://doi.org/10.1111/dom.13174.CrossRefPubMed

25.

Sussman JB, Kerr EA, Saini SD, Holleman RG, Klamerus ML, Min LC, et al. Rates of deintensification of blood pressure and glycemic medication treatment based on levels of control and life expectancy in older patients with diabetes mellitus. JAMA Intern Med. 2015;175(12):1942–9. https://doi.org/10.1001/jamainternmed.2015.5110.CrossRefPubMed

26.

McAlister FA, Youngson E, Eurich DT. Treatment deintensification is uncommon in adults with type 2 diabetes dellitus: a retrospective cohort study. Circ Cardiovasc Qual Outcomes. 2017;10(4):1–7 Available from: https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.116.003514.CrossRef

27.

Rozsnyai Z, Jungo KT, Reeve E, Poortvliet RKE, Rodondi N, Gussekloo J, et al. What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey. BMC Geriatr. 2020;20(1):1–11.CrossRef

28.

Achterhof AB, Rozsnyai Z, Reeve E, Jungo KT, Floriani C, Poortvliet RKE, et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing. PLoS One. 2020;15:1–14. https://doi.org/10.1371/journal.pone.0240463.CrossRef

29.

Qi K, Reeve E, Hilmer SN, Pearson SA, Matthews S, Gnjidic D. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949.CrossRef

30.

Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. Int J Clin Pharm. 2019;41(3):793–803. https://doi.org/10.1007/s11096-019-00829-z.CrossRefPubMed

31.

Kalogianis MJ, Wimmer BC, Turner JP, Tan ECK, Emery T, Robson L, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Soc Adm Pharm. 2016;12(5):784–8. https://doi.org/10.1016/j.sapharm.2015.12.004.CrossRef

32.

Galazzi A, Lusignani M, Chiarelli MT, Mannucci PM, Franchi C, Tettamanti M, et al. Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy. Int J Clin Pharm. 2016;38(2):454–61. https://doi.org/10.1007/s11096-016-0279-4.CrossRefPubMed

33.

Sirois C, Ouellet N, Reeve E. Community-dwelling older people’s attitudes towards deprescribing in Canada. Res Soc Adm Pharm. 2017;13(4):864–70. https://doi.org/10.1016/j.sapharm.2016.08.006.

34.

Ng WL, Tan MZW, Koh EYL, Tan NC. Deprescribing: what are the views and factors influencing this concept among patients with chronic diseases in a developed Asian community? Proc Singapore Healthc. 2017;26(3):172.CrossRef

35.

Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S. People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc. 2013;61(9):1508–14. https://doi.org/10.1111/jgs.12418.CrossRefPubMed

36.

Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673–80. https://doi.org/10.1001/jamainternmed.2018.4720.

37.

Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544 Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2014-006544.CrossRef

38.

Schuling J, Gebben H, LJG V, Haaijer-Ruskamp FM. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pract. 2012;13(1):56 Available from: https://bmcfampract.biomedcentral.com/articles/10.1186/1471-2296-13-56.CrossRef

39.

Gillespie RJ, Harrison L, Mullan J. Deprescribing medications for older adults in the primary care context: a mixed studies review. Heal Sci Reports. 2018;1(7):e45. https://doi.org/10.1002/hsr2.45.CrossRef

40.

Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807. https://doi.org/10.1007/s40266-013-0106-8.CrossRefPubMed

41.

Reeve E, Low LF, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. Br J Gen Pract. 2016;66(649):e552–60. https://doi.org/10.3399/bjgp16X685669.CrossRefPubMedPubMedCentral

42.

Luymes CH, van der Kleij RMJJ, Poortvliet RKE, de Ruijter W, Reis R, Numans ME. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50(6):446–54. https://doi.org/10.1177/1060028016637181.CrossRefPubMed

43.

Goyal P, Requijo T, Siceloff B, Shen MJ, Masterson Creber R, Hilmer SN, et al. Patient-reported barriers and facilitators to deprescribing cardiovascular medications. Drugs Aging. 2020;37(2):125–35. https://doi.org/10.1007/s40266-019-00729-x.CrossRefPubMedPubMedCentral

44.

Crutzen S, Baas G, Abou J, van den Born-Bondt T, Hugtenburg JG, Bouvy ML, et al. Barriers and enablers of older patients to deprescribing of cardiometabolic medication: a focus group study. Front Pharmacol. 2020;11(August):1–11.

45.

Martinez AI, Spencer J, Moloney M, Badour C, Reeve E, Moga DC. Attitudes toward deprescribing in a middle-aged health disparities population. Res Soc Adm Pharm. 2020;1:1–6.

46.

Lau DT, Briesacher B, Mercaldo ND, Halpern L, Osterberg EC, Jarzebowski M, et al. Older patients’ perceptions of medication importance and worth: an exploratory study. Drugs Aging. 2008;25(12):1091–75.CrossRef

47.

Pickering AN, Hamm ME, Dawdani A, Hanlon JT, Thorpe CT, Gellad WF, et al. Older patient and caregiver perspectives on medication value and deprescribing: a qualitative study. J Am Geriatr Soc. 2020;68(4):746–53. https://doi.org/10.1111/jgs.16370.

48.

Edelman M, Jellema P, Hak E, Denig P, Blanker MH. Patients’ Attitudes Towards Deprescribing Alpha-Blockers and their willingness to participate in a discontinuation trial. Drugs Aging. 2019;36(12):1133–9. https://doi.org/10.1007/s40266-019-00712-6.

49.

Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–28. https://doi.org/10.1007/s40266-016-0410-1.

50.

Green SB. How many subjects does it take to do a regression analysis. Multivar Behav Res. 1991;26(3):499–510. https://doi.org/10.1207/s15327906mbr2603_7.CrossRef

51.

World Health Organization. ATC/DDD Index 2019. 2019 [cited 2019 Nov 21]. Available from: https://www.whocc.no/atc/structure_and_principles/CrossRef

52.

Lundby C, Simonsen T, Ryg J, Søndergaard J, Pottegård A, Lauridsen HH. Translation, cross-cultural adaptation, and validation of Danish version of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire: Version for older people with limited life expectancy. Res Soc Adm Pharm. 2020;S1551–7411(20):31166–9. https://doi.org/10.1016/j.sapharm.2020.11.001.

53.

Stuckey H, Fisher L, Polonsky WH, Hessler D, Snoek FJ, Tang TS, et al. Key factors for overcoming psychological insulin resistance: An examination of patient perspectives through content analysis. BMJ Open Diabetes Res Care. 2019;7(1):e000723.CrossRef

54.

Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9. https://doi.org/10.2337/diacare.28.11.2673.CrossRefPubMed

55.

Oliveria SA, Menditto LA, Yood MU, Koo YH, Wells KE, McCarthy BD. Barriers to the initiation of, and persistence with, insulin therapy. Curr Med Res Opin. 2007;23(12):3105–12. https://doi.org/10.1185/030079907X242638.CrossRefPubMed

56.

Polonsky WH, Arsenault J, Fisher L, Kushner P, Miller EM, Pearson TL, et al. Initiating insulin: how to help people with type 2 diabetes start and continue insulin successfully. Int J Clin Pract. 2017;71(8):1–8.CrossRef

57.

Long E, Ponder M, Bernard S. Knowledge, attitudes, and beliefs related to hypertension and hyperlipidemia self-management among African-American men living in the southeastern United States. Patient Educ Couns. 2017;100(5):1000–6. https://doi.org/10.1016/j.pec.2016.12.011.CrossRefPubMed

58.

van Marum RJ, van Marum S, van Driesten S, Verdoorn S, Boxman A, Grossklaus A. Medicatie minderen bij ouderen: meningen van patiënt, apotheker en huisarts vergeleken. Ned Platf voor Farm Onderz. 2016;151(43):28.

59.

Kriegbaum M, Liisberg KB, Wallach-Kildemoes H. Pattern of statin use changes following media coverage of its side effects. Patient Prefer Adherence. 2017;11:1151–7. https://doi.org/10.2147/PPA.S133168.CrossRefPubMedPubMedCentral

60.

Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:1–10.

61.

af Wåhlberg AE, Poom L. An empirical test of nonresponse Bias in internet surveys. Basic Appl Soc Psychol. 2015;37(6):336–47. https://doi.org/10.1080/01973533.2015.1111212.CrossRef

62.

Rindfuss RR, Choe MK, Tsuya NO, Bumpass LL, Tamaki E. Do low survey response rates bias results? Evidence from Japan. Demogr Res. 2015;32(1):797–828. https://doi.org/10.4054/DemRes.2015.32.26.CrossRef

63.

Cardwell K, Smith SM, Clyne B, McCullagh L, Wallace E, Kirke C, et al. Evaluation of the general practice pharmacist (GPP) intervention to optimise prescribing in Irish primary care: a non-randomised pilot study. BMJ Open. 2020;10(6):e035087. https://doi.org/10.1136/bmjopen-2019-035087.CrossRefPubMedPubMedCentral

Title: Older people’s attitudes towards deprescribing cardiometabolic medication
Authors: Stijn Crutzen
Jamila Abou
Sanne E. Smits
Gert Baas
Jacqueline G. Hugtenburg
Mette Heringa
Petra Denig
Katja Taxis
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Sulfonylurea
Statins
Insulins
Insulins
Published in: BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-021-02249-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Older people’s attitudes towards deprescribing cardiometabolic medication

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Multi-component cognitive intervention for older adults with mixed cognitive levels: implementation and preliminary effectiveness in real-world settings

Medication adherence support of an in-home electronic medication dispensing system for individuals living with chronic conditions: a pilot randomized controlled trial

Evaluation of the efficacy of hearing aids in older adults: a multiparametric longitudinal study protocol

Systematic geriatric assessment for older patients with frailty in the emergency department: a randomised controlled trial

Socioeconomic inequalities in life expectancy and disability-free life expectancy among Chilean older adults: evidence from a longitudinal study

Is geriatric depression scale a valid instrument to screen depression in Chinese community-dwelling elderly?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page